PPAR alpha Inhibitors
2 drugsAbout PPAR alpha
PPAR alpha, or peroxisome proliferator-activated receptor alpha, is a nuclear receptor that regulates lipid metabolism. As a ligand-activated transcription factor, it influences genes involved in fatty acid oxidation and lipoprotein metabolism.
PPAR alpha is a drug target in the metabolic therapeutic area, though no genetic evidence currently links it directly to specific diseases. Drugs like FENOFIBRIC ACID and IQIRVO modulate its activity to address dyslipidemia.
PPAR alpha is targeted by two FDA-approved small molecule drugs: FENOFIBRIC ACID and IQIRVO. These drugs are marketed by Aurobindo Pharma and IPSEN, respectively, for metabolic and other indications.
Top PPAR alpha Drugs
Only two companies, Aurobindo Pharma and IPSEN, have approved drugs targeting PPAR alpha.
Low market concentration indicates relatively low barriers to entry for new PPAR alpha-targeting drugs.
PPAR alpha Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PPAR alpha, using small molecule modality.
The exclusive use of small molecules suggests an opportunity for novel modalities like antibodies or peptides.
PPAR alpha Clinical Trials 82 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PPAR alpha. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 24 | 20 | 2 | 2 | 91% |
| Phase 2 | 26 | 11 | 7 | 8 | 61% |
| Phase 3 | 18 | 7 | 2 | 9 | 78% |
| Phase 4 | 14 | 11 | 2 | 1 | 85% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved PPAR alpha drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PPAR alpha. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
PPAR alpha Drug Approval Timeline (2024 - 2024)
The first drug was approved in 2013, and the most recent in 2024, spanning 12 years.
The recent approval suggests renewed interest, but the slow pace indicates potential challenges in development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 49 (17 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PPAR alpha. A trial counts if an approved drug acting on PPAR alpha is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.